Study wrapper · #1098
Outpatient Dispensing Patterns and Changes in Tirzepatide Strength Mix in Japan: A Study Using the National Open Claims Data.
Omura T, Kamihara T Cureus. 2026.
DOI: 10.7759/cureus.113681PubMed: 42535213
Editor's note
This is a pharmacoepidemiologic description of dispensing and product-strength trends, not a study of clinical effect. It is useful market-context evidence about tirzepatide uptake in Japan but says nothing about efficacy, safety, or individual outcomes.
Plain-language abstract
This national claims-data analysis describes how tirzepatide was dispensed in Japan during fiscal year 2024, showing rising volumes and a shift toward higher-strength products dispensed outside medical institutions. It reports on prescribing and distribution patterns rather than clinical outcomes.
Related coverage
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026
Mixed
Sleeve gastrectomy versus tirzepatide to improve survival among patients with stage 5 CKD: A Markov decision analysis.
American journal of surgeryn=——2026
Mixed
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
Journal of chromatography. An=——2026